Our strategy is based on iterative improvements on the biological models and the electronic devices in parallel. This process is designed to synergistically generate improved systems that can be predictive of real biological systems, and is therefore useful for drug discovery and therapeutics.

Our group combines expertise in a wide range of disciplines including biochemistry, microbiology and cell biology on the ‘bio’ side, to materials science, electronics and chemistry on the physical sciences and engineering side.

On the materials side, we have generated significant expertise working with organic electronics, specifically conducting polymers that have been shown to be particularly apt at interfacing with biological systems. Organic bioelectronics is a field generating significant buzz in industry and amongst clinicians.